Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SR-related CTD associated factor 8 (SCAF8) is an RNA-binding protein involved in controlling mRNA processing during transcription in human cells. SCAF8 acts as an anti-terminator protein by suppressing the use of early, alternative polyadenylation sites, thereby preventing premature transcript termination and the production of non-functional, truncated mRNAs and proteins. It associates with the phosphorylated C-terminal domain (CTD) of RNA polymerase II, binds nascent RNA upstream of early polyA sites, and independently functions as a positive elongation factor for transcript progression. SCAF8 is broadly expressed across tissues, localizes to the nucleoplasm, and is essential for proper gene expression. It acts redundantly with SCAF4 for its anti-termination function; lack of both factors is lethal to cells due to widespread disruption of mRNA maturation. Currently, no approved drugs or small molecules target SCAF8 directly, and it is not regarded as a therapeutic target in standard pharmacology databases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SR-related CTD associated factor 8 (SCAF8).